Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
180 Leser
Artikel bewerten:
(0)

ViewRay' Announces World's First Patients Treated Using MRI-Guided Radiation Therapy

Finanznachrichten News

CLEVELAND, Feb. 5, 2014 /PRNewswire/ --The ViewRay' system, the world's first and only MRI-guided radiation therapy system, is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo. The ViewRay system provides a patented combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer.

MRI-guided radiation therapy enables clinicians to see a patient's internal anatomy in real-time and keep the radiation beams on target when the tumor moves during treatment. One of the initial treatments being delivered on the ViewRay system is stereotactic body radiation therapy (SBRT) for lung cancer. SBRT is a type of radiation therapy in which a few very high doses of radiation are delivered to small, well-defined tumors to kill cancer cells while minimizing exposure to surrounding healthy organs.

"Treating patients is a key milestone for ViewRay, but more importantly, it marks a significant advance in cancer care," said Chris A. Raanes, ViewRay president and CEO. "MRI-guided radiation therapy is no longer a research quest; today it has become real and offers physicians a new and powerful weapon for treating cancer."

An international leader in cancer treatment and research, the Siteman Cancer Center has a rich history of adopting and helping to develop new technology with a focus on improving patient care and outcomes.

"Real-time MR guidance offers a way to treat tumors that move with respiration," said Jeffrey Bradley, M.D., S. Lee Kling Professor of Radiation Oncology at Siteman Cancer Center and Washington University School of Medicine. "Our physicians and physicists report the ability to see tumors move in real-time during the entire treatment. This helps to ensure that tumor targets are hit and healthy tissue is spared."

About ViewRay
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system provides continuous soft-tissue imaging during radiation therapy using MRI-guidance, so that clinicians are able to see exactly where the radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.

About the Siteman Cancer Center
TheSiteman Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center in Missouri, is ranked among the top cancer facilities in the nation by U.S. News & World Report. Comprising the cancer research, prevention and treatment programs ofBarnes-Jewish HospitalandWashington University School of Medicine, Siteman also is Missouri's only member of the National Comprehensive Cancer Network. For more information, visit www.siteman.wustl.edu.

ViewRay is a trademark of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

SOURCE ViewRay Incorporated

© 2014 PR Newswire
5 heiße Wetten für den Jahresendspurt!
Nach dem unerwartet schnellen Ende der US-Wahlen mit dem Sieg des republikanischen Kandidaten Donald Trump fackelten die Aktien- und Krypto- Märkte ein wahres Kursfeuerwerk ab und bliesen zur Jahresendrallye.

Im aktuellen kostenlosen Report beleuchten wir 5 aussichtsreiche Unternehmen, die das Fundament besitzen, in den nächsten Monaten den breiten Markt zu schlagen.

Seien Sie dabei!

Fordern Sie jetzt unseren brandneuen neuen Spezialreport an und erfahren Sie, welche Aktien aufgrund ihrer Bewertung sowie charttechnischen Situation das Potenzial zu einer Outperformance besitzen.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.